Table 9 CSF findings in samples from patients with monophasic disease and from patients with relapsing disease

Pleocytosis, acute attacks

Samples

17/27 (63%)

37/74 (50%)^§

Pleocytosis, acute MY

Samples

12/14 (85.7%)

20/26 (76.9%)

Pleocytosis, acute ON

Samples

3/9 (33.3%)

12/40 (30%)

Pleocytosis, acute BRAIN

Samples

2/4 (50%)

4/6 (66.7%)

OCB, acute attacks

Samples

4/25 (16%)

5/70 (7.1%)^§

OCB, acute MY

Samples

1/12 (8.3%)

2/25 (8%)

OCB, acute ON

Samples

1/9 (11.1%)

2/38 (5.3%)

OCB, acute BRAIN

Samples

2/4 (50%)

0/6 (0%)

IgG-IF > 10%, acute attacks

Samples

1/21 (4.8%)

3/62 (4.8%)^§

IgG-IF > 10%, acute MY

Samples

1/12 (8.3%)

1/23 (4.3%)

IgG-IF > 10%, acute ON

Samples

0/6 (0%)

2/33 (6.1%)

IgG-IF > 10%, acute BRAIN

Samples

0/3 (0%)

0/5 (0%)

QAlb > Q_lim(Alb), acute attacks

Samples

12/21 (57.1%)

30/66 (45.5%)^§

QAlb > Q_lim(Alb), acute MY

Samples

8/12 (66.7%)

14/24 (58.3%)

QAlb > Q_lim(Alb), acute ON

Samples

2/6 (33.3%)

13/36 (36.1%)

QAlb > Q_lim(Alb), acute BRAIN

Samples

2/3 (66.7%)

2/5 (40%)

CSF TP elevated, acute attacks

Samples

15/24 (62.5%)

27/68 (39.7%)^§

CSF TP elevated, acute MY

Samples

9/12 (75%)

12/25 (48%)

CSF TP elevated, acute ON

Samples

4/9 (44.4%)

11/37 (29.7%)

CSF TP elevated, acute BRAIN

Samples

2/3 (66.7%)

4/5 (80%)

CSF l-lactate elevated, acute attacks

Samples

7/18 (38.9%)

8/46 (17.4%)^§

CSF l-lactate elevated, acute MY

Samples

6/10 (60%)

4/16 (25%)

CSF l-lactate elevated, acute ON

Samples

1/6 (16.7%)

4/29 (13.8%)

CSF l-lactate elevated, acute BRAIN

Samples

0/2 (0%)

0/1 (0%)

Time since attack onset, acute LPs

Days

5 (0-31)

9.5 (0-34)